[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3530 followers Created: 2025-07-02 17:51:06 UTC Citizens reiterated $CRNX Market Outperform-$90. $NBIX $CORT $IMVT $BBIO $ARGX $VRDN $AMGN $TRML $RGLS - $NVS $VRTX Citizens said in its note: "Crinetics ( $CRNX, MO, $XX PT) will present Phase X TouCAHn data for atumelnant in congenital adrenal hyperplasia (CAH) during the oral session "All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency" on Saturday, July XX. While the abstract remains embargoed, previously released data show the once-daily oral ACTH antagonist induces rapid and sustained reductions of androstenedione and 17- hydroxyprogesterone over XX weeks, with most patients normalizing A4 within two weeks (our coverage here). Importantly, atumelnant had greater A4 reductions than Neurocrine's ( $NBIX, NC) approved drug Crenessity, which could translate to greater glucocorticoid (GC) reductions (the regulatory endpoint). $CRNX will also present two posters on reductions in adrenal volume and 11-oxygenated androgens in the Phase X trial. Recall, atumelnant led to consistent decreases in adrenal size across dose cohorts, with mean reductions ranging from 1.6-5.2 mL (baseline XXXX mL). Atumelnant effectively reduced 11-oxygenated androgens, which are potent adrenal steroids and key biomarkers of adrenal androgen excess. We look forward to more details at the conference. $CRNX is kicking off its Phase X CALM-CAH study of atumelnant for CAH this half. The double-blind trial will enroll~105 adult patients randomized to XX mg atumelnant or placebo for XX weeks. The trial will include a diverse population, including patients with normal A4 levels on supraphysiologic GC doses, elevated A4 levels on supraphysiologic GC doses, and elevated A4 levels on physiologic GC doses. $CRNX also plans to start the Phase 2/3 pediatric study of atumelnant in CAH and the Phase 2/3 trial in ACTH-dependent Cushing's syndrome in 2H25. At a recent investor day, $CRNX laid out its preclinical pipeline, introducing its TSH antagonist CRN12755 for Graves' disease and thyroid eye disease (TED) and somatostatin receptor subtype-3 (SST3) agonist CRN10329 for polycystic kidney disease, with IND submissions for both expected this year." XXXXX engagements  **Related Topics** [has been](/topic/has-been) [drugs](/topic/drugs) [investment](/topic/investment) [hc](/topic/hc) [abstract](/topic/abstract) [cah](/topic/cah) [$vrtx](/topic/$vrtx) [$nvs](/topic/$nvs) [Post Link](https://x.com/Quantumup1/status/1940468288649040284)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3530 followers
Created: 2025-07-02 17:51:06 UTC
Citizens reiterated $CRNX Market Outperform-$90. $NBIX $CORT $IMVT $BBIO $ARGX $VRDN $AMGN $TRML $RGLS - $NVS $VRTX Citizens said in its note: "Crinetics ( $CRNX, MO, $XX PT) will present Phase X TouCAHn data for atumelnant in congenital adrenal hyperplasia (CAH) during the oral session "All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency" on Saturday, July XX.
While the abstract remains embargoed, previously released data show the once-daily oral ACTH antagonist induces rapid and sustained reductions of androstenedione and 17- hydroxyprogesterone over XX weeks, with most patients normalizing A4 within two weeks (our coverage here).
Importantly, atumelnant had greater A4 reductions than Neurocrine's ( $NBIX, NC) approved drug Crenessity, which could translate to greater glucocorticoid (GC) reductions (the regulatory endpoint). $CRNX will also present two posters on reductions in adrenal volume and 11-oxygenated androgens in the Phase X trial.
Recall, atumelnant led to consistent decreases in adrenal size across dose cohorts, with mean reductions ranging from 1.6-5.2 mL (baseline XXXX mL). Atumelnant effectively reduced 11-oxygenated androgens, which are potent adrenal steroids and key biomarkers of adrenal androgen excess. We look forward to more details at the conference.
$CRNX is kicking off its Phase X CALM-CAH study of atumelnant for CAH this half. The double-blind trial will enroll~105 adult patients randomized to XX mg atumelnant or placebo for XX weeks. The trial will include a diverse population, including patients with normal A4 levels on supraphysiologic GC doses, elevated A4 levels on supraphysiologic GC doses, and elevated A4 levels on physiologic GC doses.
$CRNX also plans to start the Phase 2/3 pediatric study of atumelnant in CAH and the Phase 2/3 trial in ACTH-dependent Cushing's syndrome in 2H25.
At a recent investor day, $CRNX laid out its preclinical pipeline, introducing its TSH antagonist CRN12755 for Graves' disease and thyroid eye disease (TED) and somatostatin receptor subtype-3 (SST3) agonist CRN10329 for polycystic kidney disease, with IND submissions for both expected this year."
XXXXX engagements
Related Topics has been drugs investment hc abstract cah $vrtx $nvs